ISPC (iSpecimen) Interest Expense : $-0.23 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is iSpecimen Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. iSpecimen's interest expense for the three months ended in Sep. 2024 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.23 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. iSpecimen's Operating Income for the three months ended in Sep. 2024 was $ -1.71 Mil. iSpecimen's Interest Expense for the three months ended in Sep. 2024 was $ -0.01 Mil. iSpecimen did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

iSpecimen Interest Expense Historical Data

The historical data trend for iSpecimen's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iSpecimen Interest Expense Chart

iSpecimen Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.72

-2.10

-0.24

-0.23

iSpecimen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-	-0.22	-	-	-0.01

iSpecimen Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.23 Mil.

iSpecimen (NAS:ISPC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

iSpecimen's Interest Expense for the three months ended in Sep. 2024 was $-0.01 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-1.71 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $0.28 Mil.

iSpecimen's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

iSpecimen did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

iSpecimen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 Bedford Street, Lexington, MA, USA, 02420

Website

https://www.ispecimen.com

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

Executives

Benjamin Bielak	officer: Chief Information Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley	officer: Chief Financial Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile	director	450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross	director, 10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d.	director	C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks	director	100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc	10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence	director	450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl	director	450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli	director, officer: CEO, President	450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan	director, officer: COO, Secretary, Treasurer	450 BEDFORD STREET, LEXINGTON MA 02420